TX-TANGO-NETWORKS
Tango Networks today announced Global Pass, a single rate subscription plan for Tango Extend across 39 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312069630/en/
Tango Extend Global Pass sets the new benchmark for global business mobile communications under a single subscription plan. (Photo: Business Wire)
The Tango Extend eSIM service already enables any subscriber’s smartphone to integrate directly with a company’s Unified Communications (UC) platform to provide remote employees, frontline, deskless and hybrid workers with seamless business communications.
Now, with Global Pass, Tango Extend subscribers enjoy a single fixed-rate business mobile service across 14 Home countries with seamless roaming in a further 25 Home Away countries across Europe and North America.
“Global Pass is a game-changer, enhancing the capabilities of Tango Extend to redefine how enterprises connect, communicate, and collaborate on a global basis,” said Lee Essex, Senior Vice President of Sales for Tango Networks. "With Global Pass, we empower enterprises to break free from traditional connectivity and geography constraints, fostering a new era of productivity and collaboration for the extended workforce."
Global Coverage with Borderless Roaming in 39 Countries
Global Pass liberates mobile communication from borders, enabling employees to stay connected effortlessly while traveling or working internationally.
Starting with 14 countries in the first half of 2024, Global Pass subscribers based in the USA, UK, Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Mexico, Luxembourg, Spain, Sweden, and Poland will be able to be resident or move freely between these countries and roam into 25 more countries across Europe and North America without the fear of incurring additional 'roaming' charges. Check coverage availability here: https://tango-networks.com/country-availability/
Later in 2024 and into 2025, Global Pass will expand to countries across Asia, Australasia, North and South America.
Seamless Integration for Mobile UC
Integrating with many leading UC platforms including Microsoft’s Teams Phone, Tango Extend enables workers to use their existing business numbers natively on their mobile phones, including Bring-Your-Own-Device (BYOD) mobile phones. Tango Extend provides a business e-SIM for any multi-SIM personal mobile phone. The eSIM is paid for and controlled by the business, allowing work communications and personal communications to be securely separated with dual personas. Business calls are made using the phone’s native dialer, rather than a mobile app.
Companies using Tango Extend are retiring landline desk phones, cutting expensive company-issued mobile phones, whilst at the same time reducing their carbon footprint and boosting worker productivity.
Incorporating groundbreaking fixed-mobile convergence technologies, Tango Extend is covered by more than 100 patents and has won more than 10 best new product and channel solution awards.
About Tango Networks:
Tango Networks is a pioneering force in providing cutting-edge mobile telecommunications solutions for enterprises globally. With a focus on innovation and customer-centricity, Tango Networks continues to revolutionize how businesses connect and communicate in a mobile-centric world.
Global Pass is available for immediate deployment, offering enterprises a transformative approach to mobile connectivity. For more details on Global Pass and Tango Networks' comprehensive suite of mobile telecommunications solutions, please visit tango-networks.com.
Tango Extend is a trademark of Tango Networks Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312069630/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom